Physician profile
Stephen L Vu
NPI 1124065008
$1,585.92
in general payments reported to CMS, 2019-2025
15 companies · $95.36 in 2025
The $95.36 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $111 · 2021: $158 · 2022: $500 · 2023: $397 · 2024: $186 · 2025: $95.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $732.74 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $157.63 | 2020-2024 | Dificid, Verquvo, Zerbaxa |
| Pfizer INC. | $127.44 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $118.38 | 2019-2024 | |
| Gilead Sciences, INC. | $85.27 | 2023-2024 | Veklury |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.86 | 2019-2023 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $58.11 | 2023-2025 | Ultomiris |
| Genentech USA, INC. | $56.34 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $43.10 | 2025 | Vowst |
| Shionogi INC | $35.55 | 2023-2024 | Fetroja |
| E.R. Squibb & Sons, L.L.C. | $26.90 | 2021 | |
| Vifor Pharma, INC. | $23.71 | 2021 | |
| Abbvie INC. | $21.13 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $16.82 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.